TScan to Present CD45-Targeted TCR-T Therapy Abstract at ASGCT Meeting
TScan Therapeutics secured acceptance of Abstract ID 1256 on CD45-targeted TCR-T therapies to prevent relapse after allogeneic hematopoietic cell transplantation at the ASGCT 29th Annual Meeting May 11–15 in Boston. The poster session occurs May 12 at 5:00 p.m. Eastern, and materials will be uploaded to TScan’s website.
1. ASGCT Poster Presentation
TScan will present Abstract ID 1256 on May 12 from 5:00 to 6:30 p.m. Eastern at the ASGCT 29th Annual Meeting in Boston. The poster session will showcase the company’s engineered T cell research in hematologic malignancies.
2. CD45-Targeted TCR-T Therapy
The abstract details a novel CD45-targeted TCR-T approach designed to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. This work underpins TScan’s ALLOHA Phase 1 heme trial evaluating its lead TCR-T therapy candidate.
3. Materials Availability
Following the session, presentation materials will be added to the Publications section of TScan’s website. Stakeholders and investors can review the full poster content online after May 12.